Effect of aerosolized surfactant in patients with stable chronic bronchitis: A prospective randomized controlled trial

JAMA

Volumn 278, Issue 17, 1997, Pages 1426-1431

  Anzueto, Antonio ^a   Jubran, Amal ^b   Ohar, Jill A ^c   Piquette, Craig A ^d   Rennard, Stephen I ^d   Colice, Gene ^e,f   Pattishall, Edward N ^f   Barrett, Janet ^f   Engle, Melissa ^a   Perret, Kenneth A ^a,g   Rubin, Bruce K ^c,h,i  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^e 3M COMPANY   (United States)

^f GLAXOSMITHKLINE   (United States)

^g StatCare Pulmonary Consultants   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ Brenner Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEXADECANOL; LUNG SURFACTANT; PALMITOYLGLYCEROPHOSPHOCHOLINE; PLACEBO; SODIUM CHLORIDE; TYLOXAPOL; UNCLASSIFIED DRUG; DIPALMITOYLPHOSPHATIDYLCHOLINE; FATTY ALCOHOL; MACROGOL DERIVATIVE; PHOSPHORYLCHOLINE;

ADULT; AEROSOL; AGED; ARTICLE; BRONCHUS MUCUS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; SPIROMETRY; SPUTUM ANALYSIS; TOTAL LUNG CAPACITY; BRONCHITIS; CHRONIC DISEASE; CYTOLOGY; DRUG COMBINATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; MUCOCILIARY CLEARANCE; NEBULIZER; NONPARAMETRIC TEST; PHYSIOLOGY; PROSPECTIVE STUDY; SPUTUM;

ADMINISTRATION, INTRANASAL; AEROSOLS; AGED; BRONCHITIS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOCILIARY CLEARANCE; NEBULIZERS AND VAPORIZERS; PHOSPHORYLCHOLINE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PULMONARY SURFACTANTS; RESPIRATORY FUNCTION TESTS; SPUTUM; STATISTICS, NONPARAMETRIC;

EID: 0030611938     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.17.1426     Document Type: Article

References (32)

1. Mortality patterns - United States, 1992. MMWR Morb Mortal Wkly Rep. 1994;43:916-920.
2. Aikawa T, Shimura S, Sasaki H, Takishima T, Yaegashi H, Takahashi T. Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989; 140:477-482.
3. Rubin BK, King M. The physiologic effects of smoking in COPD. J Respir Dis. 1993;14(suppl):S19-S25.
4. Bridges RB, Wyatt RJ, Rhem SR. Effects of smoking on inflammatory mediators and their relationship to pulmonary dysfunction. Eur J Respir Dis. 1986;146(suppl):145-152.
5. Rubin BK, Ramirez O, King M. Mucus rheology and transport in neonatal respiratory distress syndrome and the effects of surfactant therapy. Chest. 1992;101:1080-1085.
6. Morgenroth K, Bolz J. Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration. 1985;47:225-231.
7. Allegra L, Bossi R, Braga P. Influence of surfactant on mucociliary transport. Eur J Respir Dis. 1985;142:71-76.
8. Girod S, Zahm J-M, Plotkowski C, Beck G, Puchelle E. Role of the physicochemical properties of mucus in the protection of the respiratory epithelium. Eur Respir J. 1992;5:477-487.
9. Othis DR, Johnson M, Pedley TJ, Kamm RD. Role of pulmonary surfactant in airway closure: a computational study. J Appl Physiol. 1993;5:1323-1333.
10. Thomassen MJ, Antal JM, Connors MJ, Meeker DP, Wiedemann HP. Characterization of Exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses. Am J Respir Cell Mol Biol. 1994;10:399-404.
11. Finley TN, Ladmen AJ. Low yield pulmonary surfactant in cigarette smokers. N Engl J Med. 1972; 286:223-227.
12. Higenbottam T. Pulmonary surfactant and chronic lung disease. Eur J Respir Dis. 1987;153: 222-228.
13. De Blasio F, Diodato M, Napoletano G, Pezza A. Surfactant phospholipids in BAL fluid of laryngectomy patients suffering from chronic bronchitis. Chest. 1993;104:16S.
14. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225-244.
15. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am J Respir Dis. 1971;103:57-67.
16. Petty TL. The National Mucolytic Study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest. 1990;97:75-83.
17. King M, Rubin BK. Mucus physiology and pathophysiology: therapeutic aspects. In: Derenne JP, Similowski T, Whitelaw WA, eds. Chronic Obstructive Lung Disease. New York, NY: Marcel Dekker Inc; 1996:391-411.
18. Zahm JM, Puchelle E, Duvivier C, Didelon J. Spinability of respiratory mucous: validation of a new apparatus, the Filancemeter. Bull Eur Physiopathol Respir. 1986;22:609-613.
19. Puchelle E, Zahm JM, Petit A. Spinnability and transport properties of sputum in chronic bronchitis. Adv Exp Med Biol. 1982;144:397-398.
20. Rubin BK, Ramirez O, King M. Mucus-depleted frog palate as a model for the study of mucociliary clearance. J Appl Physiol. 1990;69:424-429.
21. Agarwal M, King M, Rubin BK, Shukla JB. Mucus transport in a miniaturized simulated cough machine: effect of constriction and serous layer simulant. Biorheology. 1989;26:977-988.
22. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995;152:1107-1136.
23. Zar JH. Biostatistical Analysis. 2nd ed. Old Tappen, NJ: Prentice Hall; 1984:162-205.
24. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;suppl:S77-S120.
25. Shim C, King GM, Williams MH Jr. Lack of effect of hydration on sputum production in chronic bronchitis. Chest. 1987;72:679-682.
26. Dueholm M, Nielsen C, Thorshauge HT, et al. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med. 1992;86:89-892.
27. Rubin BK, Ramirez OE, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest. 1996;109:348-352.
28. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990;87:9188-9192.
29. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331:637-642.
30. Fick RB, Anzueto A, Mahutte K. Recombinant DNase mortality reduction in acute exacerbations of chronic bronchitis. Clin Res. 1994;42:294. Abstract.
31. Bone RC, Fuchs H, Fox NL, et al. The chronic obstructive pulmonary disease mortality endpoint trial. Chest. 1995;108:R. Abstract.
32. Espinosa FF, Shapiro AA, Fredberg JJ, Kamm RD. Spreading of exogenous surfactant in an airway. J Appl Physiol. 1993;75:2028-2039.